MedPath

Study of Buprenorphine augmentation in regular treatment of resistant obsessive compulsive disorder

Phase 3
Conditions
Obsessive compulsive disorder.
Obsessive compulsive disorder
Registration Number
IRCT2015062422901N1
Lead Sponsor
Vice chancellor of research of Hamadan university of medical scienses
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
23
Inclusion Criteria

(a) patients with primary Obsessive Compulsive Disorder who received minimum of 2 different Selective Serotonin Reuptake Inhibitor for a period of 16 weeks in two separate rotations but failed to respond to treatment (less than 25% in symptom regression); (b)age between 18 to 60 years old; (c) scores of more than 16 according to Yale-Brown Obsessive Compulsive Scale (Y-COBS)
Exclusion criteria: (a) receiving any other opioid medications; (b) having any history of alcohol or substance abuse; (c) received any electroconvulsive therapy during the last two months; (d) having any serious diseases which require long term medical treatment such as diabetes, high blood pressure, rheumatoid arthritis, cardiovascular diseases, respiratory diseases, thyroid diseases or gastrointestinal diseases; (e) any signs of psychotic disorders, such as bi-polar schizophrenia or similar; (f)being at a great risk of suicide attempt; (g) any pregnant woman or any woman who intend pregnancy during the next 3 months; (h) any serious- non psychological diseases; (i)any upcoming surgery which needs anesthesia or deep Sedation; (j) patient is a candidate to receive electroconvulsive therapy.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Obsessive Compulsive Disorder severity. Timepoint: before intervention and end of 1,2,3,4,5 weeks after that. Method of measurement: Yale Brown Scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath